Syneos Relocates to 86,000-Plus Square Feet at 200 Vesey St.

The publicly-traded, international biopharmaceutical company signed a 10-year lease at the property owned by Brookfield Properties and American Express.

200 Vesey St. at Brookfield Place/ Image courtesy of PropertyShark, photo by Israel Peskowitz

NEW YORK CITY—Syneos Health is leasing 86,498 square feet inside the 2.5 million square-foot office building at 200 Vesey St. at Brookfield Place. Although the price was not disclosed, the gigantic biopharmaceutical organization signed a 10-year lease in the Lower Manhattan building once known as Three World Financial Center and the American Express Tower.

Syneos Health will occupy the entire 39th and 40th floors in its new space, combining multiple locations in Manhattan in late June and early July 2019. JLL represented both the tenant and building ownership and notes the relocation included negotiations of complex termination agreements from numerous other locations.

200 Vesey Street is owned by Bfp Tower C Co. and American Express Co., according to PropertyShark, which was also the source of the building image. Built in 1986, the 53-story building designed by Cesar Pelli includes 300,000 square feet of retail and dining in addition to the office towers.

Syneos Health was represented by JLL’s Erika Jean McNeil, Jonathan Fanuzzi and Kip Orban, and a brokerage team led by Paul Glickman and Matt Astrachan. They worked closely with Kevin Brandenburg, SVP and head of corporate services, at Syneos Health.  The ownership was represented by JLL’s Lisa Kiell, Michael Shenot, Ed DiTolla and Andrew Coe. Although Brookfield is an owner of the property, The Real Deal reported that the landlord who signed the lease was American Express.

“Syneos Health was looking for a large block of high-end office space in Manhattan that would allow the company to bring multiple parts of its business together under one roof,” says McNeil.

Syneos is a biopharmaceutical company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America, involved in clinical studies and drug development as well as with commercial services, according to Bloomberg.